OHDSI Home | Forums | Wiki | Github

Welcome to OHDSI! - Please introduce yourself

Hi Roy and welcome! Wondering if you or any of your colleagues might have interest in looking at cardiovascular health of patients with prostate cancer. Hormonal blockade treatments applied broadly among older men and men with metastatic disease, have been implicated in cardiovascular decline, and newer stronger hormonal treatments may be even more problematic. I am thinking that a lot of what you are doing might be ported to this application.

HI Ruth:
Thanks for the response. That would be a very interesting question - there has been some concern about testosterone replacement and CVD, but i have not heard about CV risk from androgen deprivation therapy. That would be an interesting question to ask and actually one that would be very easy to ask in a CDM.

The VA obviously would have a robust dataset for this as it is primarily older males and prostate cancer is a big issue. Androgen deprivation, in addition, is commonly used.
Roy

Hi everyone, I’m Manuel Salinas from Colombia, actually i’m working in health economics, actuary in health and Data Science, i want explore more tools and research approaches for bring more solutions in health.

Thanks

2 Likes

Hello, @mansalo92 OHDSI needs more experts on health economics. Thank you for joining.

We’ve been working on the package which can calculate DALY based on CDM data, of which name is Argos If you’re interested in this, please let me know :slight_smile:

Cheers,
Chan

Hello, I just joined the OHDSI forums. My name is Mark and I will be working on a medical data project with Northwestern University. We are looking into using the OMOP data model in this so I look forward to collaborating and learning about the model and OHDSI. Nice to meet you all!

Hello!

I’m Nicole Washington, Director of Research at Helix (https://helix.com). I’ve been lurking on the OHDSI community calls for a couple months and intend to become more involved this year, as we grow our Population Health Genomics initiatives. I’m very interested in what I can bring to the Vocabulary working group, as I have >10 years experience developing and analyzing data annotated with ontologies. In addition, I have a strong interest in properly integrating and analyzing genomic data in the CDM.

I’ve previously worked with other large consortia and community-based efforts to design and implement standards to bring together genomics and health on a variety of axes (GA4GH, ENCODE, NCBO, OBO Foundry, UDN, Monarch). I look forward to working with the OHDSI community to facilitate the integration of seemingly messy healthcare data across health systems and domains with the lofty goal to improve healthcare for the masses.

Nicole

Hello! My name is Luke and I am a Data Analyst at Regenstrief Institute (https://regenstrief.org) in Indianapolis, IN. I am gearing up for a project that involves querying our current OMOP CDM database and reporting results to a client. I’m interested in improving our CDM implementation and ETL, as well as learning more about OHDSI as a whole. I look forward to the opportunity to learn more from the community. Nice to meet everyone!

1 Like

Hello!

I’m Wendy Wong (https://wendywong.io/). I have been working with next-generation sequencing data for 10 years and have been involved in a few large cohort population genomics studies. I am interested in finding out more about OHDSI and see how I can contribute to developing models to integrate population genomics data in the CDM.

Wendy

1 Like

So many newcomers joining us in 2020! Welcome @wendy_wong, @lgolicho, @nlw, @wlodarmt

A great way to get started in the community is by joining in on our weekly community calls which take place every Tuesday from 12-1pm ET. Our next call will be on January 28th and will cover how to conduct a network research study. It’ll be a great presentation, given by @krfeeney, who will give an overview of how we collaboratively conduct research.

Details to join are available here: https://www.ohdsi.org/web/wiki/doku.php?id=projects:ohdsi_community

Hello, I’m a data scientist working for a company called Spok. I’m excited about the opportunity to participate in this community.

Hi
My name is Tae Sun Park from South Korea.
I am an endocrinologist and physician at my university hospital.
I have interested in diabetes mellitus mangement characteristics and economic efficacy.
I perform research project above mentioned topic using CDM.

Hi,
I am Dat from Vietnam,
I don’t know where to start but know community from Coursera.
Wonder whether we have reproducible research here.
Please help from all of you.

Hi…
I’m Munseob Lee from South Korea
I’m AI researcher at ETRI
I have interested in skin diagnosis by using optical device and AI…

Thanks

Hi all! I am an Italian clinical data scientist at IKNL (Integraal Kankercentrum Nederland). This is the Dutch organisation that manages the Dutch National Cancer registry. At IKNL we are in the process of making our data FAIR (Findable, Accessible, Interoperable, Reusable). To address the interoperability part we want to ETL (part of) our cancer registry data to the OMOP-CDM (Oncology extension). Hope to meet many of you at the OHDSI European Symposium in March! Cheers, Chiara

2 Likes

Ciao Chiara, benvenuta!
RB

Hello, my name is Bryan and I am an Internal Medicine doctor and clinical informatics fellow. I am interested in infusing evidenced-based medicine into the EHR via informatics, and trying to learn more data science everyday.

I am currently looking to use the OMOP CDM to create a wound care registry. Has anyone done work on a CDM for wound care? I have searched around, but have not found what I am looking for.

Hi everyone!

I am a maters student undertaking an internship with COMPASS pathways, a mental health company located in London. At COMPASS, we are preparing to initiate Phase III clinical trials for psilocybin therapy embedded in psychological support as a potential treatment for Treatment-Resistant Depression. To guide these trials, we are keen to utilize the OHDSI platform to characterize the TRD patient population better.

Honestly, I’m pretty naive to this field of study (large scale data analytics) and would appreciate any input from the community to help get my project off the ground.

I’ll be attending the European symposium in March so I’m looking forward to meeting some of you then!

Hi Maura et al -

I’m Jonathan (“Jon”) Strong. I’ve got more decades of experience than I usually care to admit in IT in all roles from architect through CIO / CTO, and have split my career about 50/50 between consulting and corporate roles. I’ve worked in many industries, leveraging experience in healthcare IT in DNA testing over the past couple of years, focused now on Adverse Events, case reporting, analytics and the like in my role as CIO for Veracuity LLC.

I’ve been reading / absorbing literature and studies (as I find them) on OHDSI and the CDM, specifically as it applies to Adverse Events recording, classification, querying and analytics. I’m weighing the cost/benefit of adopting some or all of the CDM, using it as a core data model vs being an adjunct model for import and export, etc.

I’m happy to compare notes and potentially help out if there are topics that might be in my wheelhouse - please reach out and let me know if there’s an area I might help in. You can get a sense of my experience from my LinkedIn profile: https://www.linkedin.com/in/jonstrong/ . I’ll also be on the lookout for areas I might help in as I get up to speed on the community and learn more about OHDSI. I’m based in the Princeton, NJ area - also equidistant (roughly) to NYC and Philly – happy to meet up as well. Looking forward to learning more (and hopefully making a useful contribution!).

  • Jon

Hi,

My name is Michael Shamberger and have working with OMOP format on and off for about 4 years. I have a masters degree in Machine Learning from Georgia Tech. I am interested in omop and Big Data Healthcare analytics. I have expertise in using OMOP with spark clusters. I recently contributed a module to synthea-international for the country of Finland and am planning now to do it for the entire Europe. My latest interest is seeing how massive open datasets can be used with healthcare in OMOP format to improve patient outcomes.

Mike

Hello the OHDSI community,

My name is Kazuhiko Kido. I am currently a clinical assistant professor of clinical pharmacy at West Virginia University School of Pharmacy. I am a cardiology clinical pharmacy specialist in the WVU outpatient heart failure clinic and on the WVU inpatient heart failure service. My practice and research interests are diuretic therapy optimization for heart failure patients, anticoagulation therapy, and pulmonary arterial hypertension therapy management.

I would like to collaborate with others in the community for running observational studies with databases. Especially, we are looking for some colleagues who have access to the database for heart failure.

I look forward to working with all of you in the community and hearing from you all!

Kazu

t